Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer, PSA, Infection
Interventions: Systematic Transrectal biopsy (TR-Bx), Targeted Transrectal biopsy (TR-Bx), Systematic Transperineal biopsy (TP-Bx), Targeted Transperineal biopsy (TP-Bx); Procedure
Lead sponsor: Albany Medical College; Other
Eligibility: Male only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Albany, New York

Conditions: Prostate Cancer
Interventions: 225Ac-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions: Systemic therapy, StrataNGS; Other · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostatic Neoplasms
Interventions: FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Interventions: DCC-3084; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: PCUR - 101; Drug
Lead sponsor: Pellficure Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Baltimore, Maryland • Detroit, Michigan • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: soy protein isolate, radiation therapy; Dietary Supplement · Radiation
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
Interventions: PF00562271; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Aurora, Colorado • Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: Plenaxis; Drug
Lead sponsor: PRAECIS Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 7
States / cities: La Mesa, California • Fort Myers, Florida • Panama City, Florida + 4 more

Conditions: Prostate Cancer Metastatic Disease, Prostate Cancers
Interventions: FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging; Radiation · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: AMG 208, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Diseases, Gastrointestinal Diseases, Disorder of the Genitourinary System, Gynecologic Diseases, Kidney Diseases, Liver Diseases, Pancreatic Diseases, Prostate Cancer, Spinal Disease
Interventions: Vigileo Monitor, FloTrac Sensor; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: motexafin lutetium, photodynamic therapy; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Neoplasms
Interventions: "TrueBeam" stereotactic body radiosurgery; Radiation
Lead sponsor: Albert DeNittis; Other
Eligibility: 21 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Insulin Resistance, Prostate Cancer
Interventions: Pioglitazone 30 Mg Oral Tablet, Pioglitazone placebo tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Laser Interstitial Thermal Therapy; Device
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: tamsulosin and/or dutasteride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: docetaxel; Drug
Lead sponsor: Geriatric Oncology Consortium; Other
Eligibility: 65 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: ixabepilone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 28
States / cities: Los Angeles, California • Sacramento, California • Atlanta, Georgia + 19 more

Conditions: Prostate Cancer
Interventions: Option Grid Decision Aid; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: ENV-101 (taladegib); Drug
Lead sponsor: Endeavor Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more

Conditions: Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
Interventions: Pub2Post; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions: PRL-02 injection, prednisone, dexamethasone, enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more

Conditions: Prostate Cancer
Interventions: hybrid PET-CT imaging system; Device
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older · Male only
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications

Re-treatment 225Ac-J591 for mCRPC

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Targeted Fusion Biopsy of the Prostate

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Using FAPI PET/MRI to Evaluate Prostate Cancer

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

Insulin Resistance Following ADT for Prostate CA

Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer

Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Cost Talk: Discussing Cancer Care Costs

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer